Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Active not recruiting 3Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Sarcoma 1NET 1Gynecologic 1Endocrine 1Dermatologic 1

Conditions

Carcinoma, Hepatocellular 4Colorectal Neoplasms 3Neoplasms 2Neoplasm Metastasis 1Melanoma 1Liver Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Neoplasms 1Digestive System Neoplasms 1Desmoid Tumors 1Adrenocortical Carcinoma 1

Interventions

Bevacizumab 69atezolizumab 54lenvatinib 42durvalumab 42Nivolumab 38pembrolizumab 35tremelimumab 28Magnetic Resonance Spectroscopy 21Specimen Handling 19tislelizumab 18sintilimab 17Ipilimumab 15Sorafenib 14regorafenib 13cabozantinib 13Radiosurgery 13Radiotherapy 12apatinib 11Blood Specimen Collection 11Immunoglobulin G 10camrelizumab 9Immune Checkpoint Inhibitors 9Disulfides 9X-Rays 8Cyclophosphamide 8donafenib 7Oxaliplatin 7Immunotherapy 7Folfox protocol 7Fluorouracil 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × E-7386 × 1 year × Clear all
NCT04008797 2026-03-24

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Eisai Inc.

Phase 1/2 Active not recruiting
301 enrolled
GastrointestinalGynecologic

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03264664 2026-03-06

Study of E7386 in Participants With Selected Advanced Neoplasms

Eisai Inc.

Phase 1 Active not recruiting
60 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT03833700 2026-02-27

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

Eisai Inc.

Phase 1 Active not recruiting
70 enrolled
EndocrineGastrointestinalNETSarcoma

Gastro-enteropancreatic neuroendocrine tumor, Digestive System Neoplasms, Carcinoma, Hepatocellular, Colorectal Neoplasms, Desmoid Tumors, Adrenocortical Carcinoma

NCT05091346 2025-10-24

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

Eisai Inc.

Phase 1/2 Completed
89 enrolled 24 charts
DermatologicGastrointestinal

Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡